1. Introduction {#sec1}
===============

Cis-diamminedichloroplatinum (CDDP), commonly known as cisplatin, is a chemotherapeutic agent used in the treatment of various cancers including carcinomas, germ cell tumors, lymphomas, and sarcomas. Its antitumor effect is thought to reflect its ability to cross-link with purine bases on DNA, thus interfering with DNA repair mechanisms and leading to DNA damage and tumor cell apoptosis \[[@B1]\]. However, cisplatin is also known to be associated with many adverse effects including gastrointestinal disturbances, hearing loss, allergic reactions, and a multitude of renal problems including electrolyte disturbances, renal tubular acidosis, acute kidney injury with reduced glomerular filtration, Fanconi syndrome, nephrogenic diabetes insipidus, and renal salt wasting (RSW). The pathogenesis of cisplatin-induced renal injuries is thought to be due to renal vasoconstriction and cellular apoptosis and necrosis mediated by altered cell cycle regulation, death receptor signaling, and increased oxidative stress and inflammatory state \[[@B1]--[@B3]\].

In a recent literature review, Hamdi et al. analyzed 18 patients who were reported with cisplatin-induced RSW. Patients developed RSW as soon as 12 hours and up to 4 months following cisplatin therapy. Cisplatin dosage used ranged from 80 to 600 mg/m^2^. Renal salt wasting typically only requires transient normal saline (NS) support. With the exception of one patient who required approximately 2.6 L of 3% saline infusion over 2 days, all 17 others only required normal saline support with or without supplemental oral sodium chloride tablets \[[@B4], [@B5]\]. We herein report a severe RSW case that required 12 liters of 3% saline (6156 mEq Na) over a 3.5-week course, followed by oral sodium chloride supplement for an additional 2 weeks. Preventive and therapeutic considerations for cisplatin-induced RSW will also be discussed.

2. Case Presentation {#sec2}
====================

A 57-year-old woman presented with 4 weeks of shortness of breath, dyspnea on exertion, and nonproductive cough. Imaging studies revealed a lung mass extending into the mediastinum with narrowing of the left pulmonary artery and total left upper lobe collapse. Patient was diagnosed with limited stage small cell carcinoma of the lung (SCCL). Initial therapy included cisplatin 80 mg/m^2^ on day 1 and etoposide 100 mg/m^2^ on days 1 to 3 with plan to include radiation at cycle 2. Prior to the administration of cisplatin, patient\'s serum sodium (SNa) was 134--137 mEq/L. Following the first cisplatin dose, her SNa decreased to 133 mEq/L and 125 mEq/L by 24 and 48 hours, respectively. The acute hyponatremia was initially attributed to the continuous infusion of 5% dextrose half-normal saline in association with presumed lung cancer induced SIADH. However, despite empirical free water restriction, her SNa decreased to 119 mEq/L within 72 hours. Patient developed acute headache, nausea, and fatigue. Renal service was consulted.

Medications included fluticasone nasal spray twice daily, amoxicillin-clavulanic acid 875 mg twice daily, omeprazole 20 mg daily, and empirical intravenous stress dose of hydrocortisone 100 mg q 8 h. As needed medications included metoclopramide 10 mg q 6 h and albuterol 2.5 mg nebulizer treatment q 4 h.

Physical exam revealed blood pressure 123/76 mmHg, heart rate 70 beats per minute, and respiratory rate 18 per minute. Patient was uncomfortable with generalized headaches and nausea but alert and oriented to situation, person, place, and time. Oral mucosa was dry. Heart, lungs, abdomen, and extremities were unremarkable. Neurological exam was nonfocal.

3. Results {#sec3}
==========

*Laboratory Findings*. Urine studies revealed osmolality (Uosm) 693 mosm/kg, UNa 205 mEq/L, and potassium (UK) 40 mEq/L in association with increasingly high urine output (average 100--150 mL/h, up to 600 mL/h of urine with UNa + UK up to 265 + 73 mEq/L, resp.). Cisplatin-induced proximal tubular injury with sodium wasting was suspected. Additional laboratory testing revealed glucosuria in the absence of significant serum hyperglycemia (urine glucose 1000 mg/dL, concurrent serum glucose ranged from 117 mg/dL to 141 mg/dL), low-molecular weight proteinuria (0.3 g protein/g creatinine, concurrent albumin/creatinine ratio of 27.7 mcg/mg creatinine), and hypophosphatemia (2.4 mg/dL from baseline of 4.2 mg/dL 1 week previously), all consistent with proximal tubular injury. Serum calcium was also noted to trend downwards from a baseline of 8.78 ± 0.46 mg/dL two days before to 8.25 ± 0.39 mg/dL two days following cisplatin therapy. There was no change noted in serum magnesium. Other routine evaluations for hyponatremia including thyroid stimulating hormone and morning serum cortisol levels were within normal limits.

Patient was started on 3% saline infusion. Her daily effective electrolyte loss (urine sodium and potassium) averaged at 634 ± 183 mEq/d, with a maximum of 1050 mEq.

Patient required approximately 12 L of 3% saline infusion over a 3.5-week period to correct the initial hyponatremia and maintain salt equilibrium prior to gaining sufficient renal recovery for switching to oral sodium supplements. During the worst phase of renal salt wasting, patient required up to 47 g of NaCl or 18.5 g of sodium supplement daily. During the natriuretic phase, attempts to slow her glomerular filtration, thus filtered sodium and potassium load, included ibuprofen 200 mg thrice daily and benazepril 10 mg twice daily ([Table 1](#tab1){ref-type="table"}). It is unclear if our medical therapy ameliorated any renal salt wasting. Addition of fludrocortisone 0.1 mg bid empirically prior to resulting of cortisol did not appear to ameliorate the massive natriuresis. Patient also received intermittent K-phosphate and magnesium supplement during the hospital course. Full clinical renal recovery occurred by 5.5 weeks.

4. Discussion {#sec4}
=============

In the setting of malignancy, hyponatremia commonly arises from excess free water intake in association with SIADH, poor solute intake, or, less commonly, adrenal insufficiency due to metastatic disease. Since current patient was initially euvolemic and had no problem with oral intake or known adrenal insufficiency, the diagnosis of SIADH was entertained. Despite empirical free water restriction of one liter a day, patient developed rapid worsening hyponatremia (SNa dropped from 125 mEq/L to 119 mEq/L within eight hours) and acute onset headaches, nausea without vomiting, and clinical evidence of hypovolemia (dizziness and dry oral mucosa) in association with polyuria (up to 4 L a day) of high urine sodium plus potassium content ([Table 1](#tab1){ref-type="table"}). The worsening hyponatremia despite free water restriction and inappropriate and incessant polyuria of high urinary electrolyte content despite volume depletion ruled out SIADH while raising concerns for either cisplatin-induced RSW or undiagnosed adrenal insufficiency. Both SIADH and adrenal insufficiency were eventually definitively ruled out with low vasopressin level (2.4 pg/mL normal range \[1.0 to 13.3 pg/mL\]) and normal morning cortisol level and lack of response to empirical fludrocortisone therapy, respectively. The diagnosis of cisplatin-induced RSW was thus made.

Cisplatin-induced kidney injury is rare but may lead to acute tubulointerstitial nephritis, tubular necrosis, proximal S3 tubular damage with salt wasting (K^+^, Mg^2+^, Ca^2+^, PO~4~^2−^), Fanconi syndrome, and even nephrogenic diabetes insipidus. Given significant natriuresis and hypophosphatemia, mild tubular proteinuria, and glucosuria in the absence of hyperglycemia, patient was felt to have developed Fanconi syndrome and RSW. Of interest, patient\'s daily urinary sodium loss was up to 8.9-fold the sodium content of her daily hospital-prepared meals (average sodium content of 2.0 ± 0.2 gm daily), assuming she ate all of her meals. To our knowledge, this is the most severe case of cisplatin-induced RSW ever reported. The reason for severe salt wasting in current case is not known. Patient has no underlying kidney disease and was not receiving any diuretic or nephrotoxic agent that could have potentiated the natriuresis. While we successfully supported patient with high volume 3% saline followed by salt tablets, preventive measures are vital.

Normal saline support during cisplatin therapy is likely the key preventive therapy. The protective effects of NS are thought to involve the ability of the chloride ion concentration to stabilize the CDDP molecule, suppress the formation of CDDP metabolites, and reduce the conversion of CDDP to its aquated products. The latter have higher protein binding capacity and thus greater tissue accumulation and damage \[[@B6]\].

Despite the lack of clinical data, concurrent use of commonly used antioxidants including N-acetylcysteine, vitamin C, and vitamin E has been suggested due to their reported efficacy in animal studies and low toxicity profile. Other clinically available agents considered for renoprotection against cisplatin include salicylates for anti-inflammation, allopurinol for the reduction of reactive oxygen species generation, fibrates for the reduction of free fatty acid accumulation and suppression of apoptosis, and resveratrol for antioxidative, anti-inflammatory, and cytoprotective properties \[[@B2]\].

Alternatively, replacement of cisplatin with carboplatin may be considered in cases with either known contraindication with cisplatin or documented severe cisplatin-induced nephrotoxicity. Nonetheless, it must be recognized that cisplatin has unequivocal superiority over carboplatin in terms of antitumor effect on various malignancies \[[@B7]\]. Subsequent continuation of cisplatin administration can become a difficult clinical decision and must be carefully discussed among the healthcare team and affected patients.

5. Conclusions {#sec5}
==============

Clinicians must exert great caution when administering cisplatin due to its severe and potentially life-threatening salt wasting complication. Preventive measures, particularly early normal saline infusion with or without concurrent use of antioxidants, anti-inflammatory agents, or both, must be considered to prevent adverse outcomes. In patients with established severe cisplatin-induced RSW, considerations for an alternative agent may be advisable.
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Hospital course of patient with cisplatin-induced renal salt wasting.

  Hospital day   Laboratory findings       Urine volume (mL)   Total  (Na + K) urinary loss (mEq/L)   Management                                    
  -------------- ------------------------- ------------------- -------------------------------------- ------------ ----- ------ ------ ------------ ---------
  1              138                                                                                                                   Cisplatin     
  2              133                                                                                                                                 
  3              125, 122, 119, 124, 123   205 + 40            693                                    262          3.1                              300
  4              125, 122                  212 + 21            907                                                 2.8   3800   885                 800
  5              124, 127, 126             190 + 38            806                                                 2.7   4050   923                 875
  6              129, 133, 128, 132        242 + 42            847                                                 2.8   3100   880                 750
  7              130, 136                  270 + 46            832                                                 3     2450   774                 500
  8              133, 128, 134             250 + 34            903                                                 2.9   2445   694                 670
  9              132, 122, 124             250 + 32            760                                                 2.8   2460   693                 1400
  10             132, 131, 130, 135        245 + 15            636                                                 2.7   2485   646                 850
  11             134, 133                  235 + 56            827                                                 2.9   1630   474    Benazepril   650
  12             136, 133                  212 + 23            810                                                 2.8   2425   569                 500
  13             133, 129                  265 + 42            768                                                 2.7   1950   598                 600
  14             134, 131                  258 + 41            731                                                 3.1   2500   747    Ibuprofen    0
  15             132, 130                  246 + 73                                                                3.1   1820   580                 1000
  16             130, 129                  246 + 22            637                                                 3.2   1925   515                 500
  17             129, 138, 126, 130, 131   199 + 87            734                                                 4.1   2375   679                 500
  18             131, 131                  189 + 39                                                                4.5   2850   649                 1000
  19             138, 138, 135             255 + 54            783                                                 3.1   2200   679                 500
  20             135                       162 + 44            787                                                       3600   741                 0
  21             135                       232 + 54            540                                                       3670   1049                0
  22             130, 129, 131                                                                                           2650   0                   0
  23             126, 127                  225 + 43            660                                                       1750   469                 250
  24             131, 131, 127             250 + 46            774                                                       1600   473                 250
  25             130, 127, 131, 134        147 + 69            625                                                       1750   378                 250
  26             135, 135                  197 + 21            528                                                       1800   392                  
  27             139                       145 + 19            404                                                       1700   278                  
  28             137, 130, 134             218 + 26            675                                                       2225   542                  
  29             131, 135                  209 + 47                                                                      2100   537                  
  30             132                                                                                                     1020                        
  31             138                                                                                                                                 
  *Total*                                                                                                                                           *12145*

SNa: serum sodium; U(Na + K): urine sodium plus potassium; Uosm: urine osmolality; Sosm: serum osmolality; SPhos: serum phosphorus; NS: normal saline.
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